Omnicell to Present Expanded Medication Management Integration at the European Association of Hospital Pharmacists Congress

March 25, 2015

Hamburg, Germany

Omnicell, Inc., (NASDAQ: OMCL) will exhibit the integration of its automated medication cabinets with MACH4’s modular robotic solutions at the European Association of Hospital Pharmacists (EAHP) 25-27 March.  Omnicell recently announced its agreement to purchase MACH4 Pharma Systems and the EAHP Congress will be the first event to highlight the full spectrum of medication products that Omnicell will be able to offer for the hospital, community and home settings, pending completion of Omnicell’s acquisition of MACH4 Pharma Systems.

MACH4’s modular robotic solutions allow for dispensing medications in original manufacturers’ packages and complement the innovative software capabilities of Omnicell dispensing systems.  The joint Omnicell/MACH4 exhibit will feature the MACH4 robotic medication management systems integrated with the Omnicell automated dispensing cabinet and Savvy mobile medication workstation.  Omnicell’s medication adherence packaging solutions will also be showcased. These innovative solutions span the continuum of care to help meet the unique demands of Omnicell’s growing customer base worldwide.

One of the hospitals currently using the integrated medication automation is St. Mary’s Hospital, the main facility of the Isle of Wight NHS Trust.  St. Mary’s is the only fully integrated provider in England for acute hospital, community, mental health and ambulance services and is using Omnicell medication management systems in all care areas of the hospital.  Omnicell’s medication cabinets are automatically refilled through integration with the MACH4 robotic dispensing system, which is based in the hospital pharmacy.

“This fully integrated solution, supported by a grant from the NHSE Technology Fund, helps to increase efficiency and improve patient safety of ward based dispensing,” said Gillian Honeywell, chief pharmacist at St. Mary’s hospital.  “The integration of Omnicell and MACH4 has significantly reduced data entry and eliminated errors in ward stock replenishment.  The time savings for pharmacy and nursing with this integration has been tremendous. We have completely changed the way we work – within weeks of installing the MACH4 robot integrated with the Omnicell medication dispensing system and our electronic prescribing system, we were able to allocate more staff time on wards caring for patients,” Honeywell added.

Also during the conference Omnicell will co-sponsor, along with its UK supplier, Avantec, a satellite symposium titled “Omnicell – Closing the Loop in Medicines Administration”.  This symposium will be held Thursday 26 March from 15:00 – 16:30 in Hall 4 of the CCH - Congress Center Hamburg.

“We are very excited to introduce the European market to this example of the integration of Omnicell dispensing cabinets with the MACH4 robot,” said Arthur Van Dongen, vice president and general manager, EMEA for Omnicell.  “It is anticipated that Omnicell’s acquisition of MACH4 would result in a fully integrated solution for pharmacy and nursing, and provide significant benefits in the medication dispensing processes by helping to improve efficiency, accuracy and patient safety.  We are proud to provide solutions that echo the EAHP 2015 programme, which is organized around the topic the hospital pharmacist's agenda – patient safety first.”

About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the acquisition of MACH4 Pharma Systems and the benefits thereof, including the integration of Omnicell’s and MACH4’s and the anticipated benefits thereof, including, increased efficiency, accuracy and patient safety. These forward-looking statements are based on Omnicell’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Omnicell’s ability to complete the acquisition on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of closing conditions, including, but not limited to risks associated with business combination transactions, such as the risk that acquired business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the reaction of the combined company’s customers and potential customers, the perceived complementary nature of the combined company’s products and solutions, uncertainty of the expected financial performance, market opportunities and results of the combined company following completion of the proposed acquisition; and the possibility that if Omnicell does not achieve the perceived benefits of the proposed acquisition of MACH4 as rapidly or to the extent anticipated by financial analysts or investors, the market price of Omnicell stock could decline; as well as other risks related Omnicell’s business, and those other risks detailed from time to time under the caption “Risk Factors” and elsewhere in Omnicell’s SEC filings and reports, including in the Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Omnicell undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.